Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error

Summary

AccuScan technology significantly reduces whole genome sequencing errors for cell-free DNA analysis. This breakthrough enables highly sensitive detection of molecular residual disease (MRD) and predicts relapse across multiple cancer types.